IP Library Granted Patent US 10,973,862
Granted Patent B2
US 10,973,862 · App. 16/060,765 · Granted Apr 13, 2021

Patent

Inventors: Barry Kiely (Cork, IE); Eileen Frances Murphy (Cork, IE); Selena Healy (Tipperary, IE)
Assignee: PrecisionBiotics Group Limited
A61K35/745A23L33/135A23L33/30A61P3/04C12N1/20C12R1/01A23V2002/00A23V2200/3204A23V2200/332
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,973,862
App. No.
16/060,765
Granted
Apr 13, 2021
Kind
B2
Abstract

Bifidobacterium longum AH1362 (NCIMB 41715) produces a polysaccharide and increases energy excretion. The strain is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.

Claims (18)

1. A formulation for oral administration to a subject, the formulation comprising a strain of Bifidobacterium longum AH1362 deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB) under accession number NCIMB 41715 and an ingestible carrier, wherein the formulation is in a form of a tablet or a powder.

2. The formulation as claimed in claim 1 which further comprises a probiotic material.

3. The formulation as claimed in claim 1 which further comprises a prebiotic material.

4. The formulation as claimed in claim 1 wherein the ingestible carrier comprises a food product.

5. The formulation as claimed in claim 1 which further comprises at least one of a protein or a peptide comprising glutamine/glutamate, a lipid, a carbohydrate, a vitamin, a mineral, a trace element, or a combination thereof.

6. The formulation as claimed in claim 1 wherein the strain is present in an amount of more than 10 6 cfu per gram of the formulation.

7. The formulation as claimed in claim 1 which further comprises an adjuvant.

8. The formulation as claimed in claim 1 which further comprises a bacterial component.

9. The formulation as claimed in claim 1 which further comprises a drug entity.

10. The formulation as claimed in claim 1 which further comprises a biological compound.

11. The formulation as claimed in claim 1 , wherein the strain of Bifidobacterium longum AH1362 is in the form of a powder.

12. The formulation as claimed in claim 11 , wherein the formulation is in the form of a freeze-dried powder.

13. The formulation as claimed in claim 1 wherein the strain is in a form of viable cells or non-viable cells.

14. A foodstuff comprising the formulation of claim 1 .

15. A medicament comprising the formulation of claim 1 .

16. A capsule comprising the formulation of claim 1 , wherein the formulation is in the form of a powder.

17. A method for preventing or treating a health condition, comprising administering a composition comprising a strain of Bifidobacterium longum AH1362 deposited with the National Collection of Industrial, Food and Marine Bacteria (NCIMB) under accession number NCIMB 41715 and ingestible carrier to a subject in need thereof, wherein the formulation is in a form of a tablet or a powder.

18. The method of claim 17 , wherein the health condition includes one or more of obesity, obesity-related metabolic syndrome, or non-alcoholic fatty liver disease (NAFLD).

Assignments (2)
CHANGE OF NAME Recorded Jan 10, 2020
From: ALIMENTARY HEALTH LIMITED
To: PRECISIONBIOTICS GROUP LIMITED
Reel/Frame 051480/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2018
From: KIELY, BARRY; MURPHY, EILEEN FRANCES; HEALY, SELENA
To: ALIMENTARY HEALTH LIMITED
Reel/Frame 046958/0661 →
Priority Claims (1)
EP 15199660 · Dec 11, 2015 · regional
Continuity (1)
Related Publication 20190111090A1 · Apr 18, 2019